In breast cancer, inhibiting EMT by overexpressing miR‐200, a well‐known microRNA that directly targets ZEB1/2, does not affect lung metastasis, but contributes to recurrent lung metastasis after chemotherapy [29]. Here, ZEB1 is linked to breast carcinoma.